Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells by Halim, Timotheus Y F et al.
 
 
University of Birmingham
Tissue-restricted adaptive type 2 immunity is
orchestrated by expression of the costimulatory
molecule OX40L on group 2 innate lymphoid cells
Halim, Timotheus Y F; Rana, Batika M J; Walker, Jennifer A; Kerscher, Bernhard; Knolle,
Martin D; Jolin, Helen E; Serrao, Eva M; Haim-Vilmovsky, Liora; Teichmann, Sarah A;
Rodewald, Hans-Reimer; Botto, Marina; Vyse, Timothy J; Fallon, Padraic G; Li, Zhi; Withers,
David R; McKenzie, Andrew N J
DOI:
10.1016/j.immuni.2018.05.003
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Halim, TYF, Rana, BMJ, Walker, JA, Kerscher, B, Knolle, MD, Jolin, HE, Serrao, EM, Haim-Vilmovsky, L,
Teichmann, SA, Rodewald, H-R, Botto, M, Vyse, TJ, Fallon, PG, Li, Z, Withers, DR & McKenzie, ANJ 2018,
'Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L
on group 2 innate lymphoid cells', Immunity, vol. 48, no. 6, pp. 1195-1207.e6.
https://doi.org/10.1016/j.immuni.2018.05.003
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 29/06/2018
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
ArticleTissue-Restricted Adaptive Type 2 Immunity Is
Orchestrated by Expression of the Costimulatory
Molecule OX40L on Group 2 Innate Lymphoid CellsGraphical AbstractHighlightsd Tissue-specific ILC2s are the primary source of OX40L after
IL-33 stimulation
d ILC2s from Il7rCreTnfsf4fl/fl mice do not express OX40L upon
IL-33 stimulation
d OX40L expression by ILC2s is required for IL-33-driven Th2
and Treg cell expansion
d Il7rCreTnfsf4fl/fl mice have impaired Th2 and Treg cell
responsesHalim et al., 2018, Immunity 48, 1195–1207
June 19, 2018 ª 2018 MRC Laboratory of Molecular Biology.
Published by Elsevier Inc.
https://doi.org/10.1016/j.immuni.2018.05.003Authors
Timotheus Y.F. Halim,
Batika M.J. Rana,
Jennifer A. Walker, ..., Zhi Li,
David R. Withers,
Andrew N.J. McKenzie
Correspondence
tim.halim@cruk.cam.ac.uk (T.Y.F.H.),
anm@mrc-lmb.cam.ac.uk (A.N.J.M.)
In Brief
Type 2 immunity underpins diverse
processes central to tissue homeostasis,
allergic inflammation, and anti-helminth
immunity. Halim et al. demonstrate that
the local expansion of Th2 and Treg cells
in response to the alarmin IL-33 is
dependent on the expression of the
costimulatory molecule OX40L by type 2
innate lymphoid cells (ILC2s), revealing a
central role for the IL-33-ILC2-OX40L
pathway in the orchestration of type 2
immunity.
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The local regulation of type 2 immunity relies on
dialog between the epithelium and the innate and
adaptive immune cells. Here we found that alarmin-
induced expression of the co-stimulatory molecule
OX40L on group 2 innate lymphoid cells (ILC2s) pro-
vided tissue-restricted T cell co-stimulation that was
indispensable for Th2 and regulatory T (Treg) cell re-
sponses in the lung and adipose tissue. Interleukin
(IL)-33 administration resulted in organ-specific
surface expression of OX40L on ILC2s and the
concomitant expansion of Th2 and Treg cells,
which was abolished upon deletion of OX40L on
ILC2s (Il7raCre/+Tnfsf4fl/fl mice). Moreover, Il7raCre/+
Tnfsf4fl/fl mice failed to mount effective Th2 and
Treg cell responses and corresponding adaptive
type 2 pulmonary inflammation arising from Nippos-
trongylus brasiliensis infection or allergen exposure.
Thus, the increased expression of OX40L in response
to IL-33 acts as a licensing signal in the orchestration
of tissue-specific adaptive type 2 immunity, without
which this response fails to establish.
INTRODUCTION
Type 2 immunity underpins numerous key homeostatic and im-
mune processes in health and disease (Pulendran and Artis,
2012). The type 2 cytokine environment is regulated at the tissue
level by the release of epithelium-derived type 2 cytokines,
including interleukin (IL)-25, thymic stromal lymphopoietin
(TSLP), and the alarmin IL-33. Thesemolecules elicit the produc-Immunity 48, 1195–1207, June 19, 2018 ª 2018 MR
This is an open access article undtion of type 2 effector cytokines from immune cells, which are
fundamental for diverse functions, ranging from anti-helminth
parasite immunity to allergic inflammation, wound healing re-
sponses, and metabolism (Gause et al., 2013; Man et al.,
2017). Indeed, the tissue- and context-specific production of
type 2 alarmins likely governs their downstream physiological
functions. Adaptive type 2 immunity is driven by CD4+ T
helper 2 (Th2) cells, which are the major source of type 2 in-
flammatory cytokines. However, CD4+ regulatory T (Treg) cells
are increasingly associated with some type 2 inflammatory
functions, such as wound healing and adipose tissue homeo-
stasis (Odegaard and Chawla, 2015; Panduro et al., 2016).
The nature of the Treg cell association with type 2 immunity re-
mains enigmatic and ranges from suppressive to synergistic.
Indeed, Th2 and Treg cell subsets can respond directly to
type 2 alarmins such as IL-33 and express overlapping tran-
scriptional and functional programs (Siede et al., 2016; Wohlfert
et al., 2011). While adaptive type 2 immune cells are rare in
most tissues under homeostatic conditions, innate group 2
innate lymphoid cells (ILC2s) are tissue-resident cells and
rapidly respond to type 2 alarmins by producing factors shared
with both Th2 (IL-5 and IL-13) and Treg (Amphiregulin) cell
function. The division of labor, and interactions, between
ILC2s and adaptive type 2 immune cells remains a fundamental
and unresolved question.
Roles for ILC2s directly regulating CD4+ T helper cell activation
have been proposed recently (Drake et al., 2014; Mirchandani
et al., 2014; Oliphant et al., 2014; von Burg et al., 2014).
MHCII-expressing ILC2s interact with antigen-specific T cells
to instigate a dialog in which ILC2 and T cell crosstalk contrib-
utes to their mutual maintenance, expansion, and cytokine pro-
duction (Mirchandani et al., 2014; Oliphant et al., 2014). ILC2s
can also modulate T cell function, not by acting directly on naive
CD4+ T cells but by collaborating with dendritic cells (DCs) to
induce Th2 cell activation (Halim et al., 2014, 2016). Notably,C Laboratory of Molecular Biology. Published by Elsevier Inc. 1195
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. ILC2s Are Required for Th2 and Treg Cell Response to IL-33
(A–C) WT mice were treated with PBS or IL-33 (i.n., day 0 and 1) and analyzed on day 5 for Foxp3 and GATA3 expression in lung CD4+ T cells (A). Indicated
populations (IL-33-treated shown) were subsequently analyzed for expression of Helios and neuropilin-1 (Nrp-1) (B) and CTLA4 (C).
(D) RNA-seq was performed on lung Foxp3egfp+GATA3hDC2+ and Foxp3egfp+GATA3hDC2 Treg cells, Foxp3egfpGATA3hDC2+ Th2 cells, and ILC2s on day 5 after
treatment with PBS or IL-33 (i.n., day 0 and 1). Shown is a Venn diagram of transcripts expressed in each cell population (>10 RPKM).
(E) Mice were treated with IL-33 and 2W1S-peptide as indicated (i.n., day 0 and 1), followed by quantification of 2W1S-Tetramer+/ Foxp3+GATA3+ Treg cells and
Foxp3GATA3+ Th2 cells in the lung on day 5.
(legend continued on next page)
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the importance of the local tissue environment is highlighted by
the observation that the response to systemic antigen exposure
is not sensitive to the absence of ILC2s (Gold et al., 2014). In
contrast to thesemodels where ILC2 help initiates andmaintains
type 2 responses, it has been proposed that ILC2 and CD4+
T cell responses develop independently and that it is the tis-
sue-localized exposure of these cells to locally produced cyto-
kines that acts as a checkpoint in the activation of a type 2
response, rather than the interaction of these cells within the tis-
sue (Van Dyken et al., 2016). Thus, the interplay between ILC2s
and adaptive type 2 immune cells is likely to differ depending
on anatomical location, activating signals, and temporal phase
of the immune response.
In addition to the MHCII-mediated activation of helper T cells,
the cognate interaction between the co-stimulatory molecule
ICOSL on ILC2s and ICOS on T cells promotes Treg cell
accumulation following IL-33 administration (Molofsky et al.,
2015). This is in addition to the ICOS-ICOSL autocrine signals
that can enhance ILC2 proliferation (Maazi et al., 2015). An
in vitro study also suggested the potential contribution for
OX40 ligand (OX40L) expressed on ILC2s for the co-stimulation
of T cells, though its role in vivo was not explored (Drake
et al., 2014). Ligation of OX40 by OX40L, encoded respectively
by the genes Tnfrsf4 and Tnfsf4, provides an important
signal for the expansion or survival of Th2 cells, while less
is understood about these effects on Treg cells (Croft, 2010;
Webb et al., 2016). OX40 is constitutively expressed at
baseline on Treg cells and is induced on Th2 cells after T cell
receptor (TCR)-mediated activation, while OX40L expres-
sion is reported on numerous immune cells but most notably
on professional antigen-presenting cells such as DCs. Specif-
ically, OX40L expression by DCs is important for effective
Th2 cell responses to helminth-derived antigen (Jenkins et al.,
2007). OX40 binding to OX40L activates TNF receptor associ-
ated factor (TRAF) signaling pathways that synergize with
TCR or cytokine-derived stimulation (Croft, 2010; Webb
et al., 2016).
Here we found that ILC2s express high levels of OX40L
after exposure to IL-33. No other immune cells that we analyzed
in the lung, including lung DCs, expressed OX40L in vivo
in response to exogenously administered type 2 alarmins,
including TSLP. OX40L expression on ILC2s was tissue
restricted and correlated with local expansion of adaptive type
2 immune cells. ILC2s and OX40 were critical for tissue-specific
IL-33-driven Th2 and Treg (preferentially GATA3+ Treg) cell re-
sponses. ILC2-targeted deletion of OX40L (Il7rCre/+Tnfsf4fl/fl)
significantly impaired Th2 and Treg cell expansion following
allergen exposure and Nippostrongylus brasiliensis helminth
infection, with profound effects on overall type 2 inflammation.
Thus, OX40L expression on ILC2s in response to epithelial
cell-derived alarmins is a critical checkpoint for orchestrating
adaptive type 2 responses.(F) Mice were treated with IL-33 (i.n., day 0 and 1) followed by quantification of Fox
(G) PBS- or diphtheria toxin (DTX)-treated ICOS-Tmicewere administeredwith IL-
of 2W1S-Tetramer+/ Foxp3+GATA3+ Treg and Foxp3GATA3+ Th2 cells in the
Bar graphs indicate mean (±SEM). (A)–(C), three repeat experiments, mean per
experiments; (F), ANOVA, two repeat experiments; (G), ANOVA, three repeat
****p% 0.0001. See also Figures S1 and S2.RESULTS
ILC2 Are Critical for Regulating Adaptive Type 2
Immunity
Airway exposure to the protease allergen papain results in IL-33-
dependent accumulation of GATA3+ ILC2s and Th2 cells. The
transcription factor GATA3 is critical for the development and
function of type 2 cytokine-producing ILC2s and Th2 cells and
is also expressed in a subset of Foxp3+ Treg cells associated
with enhanced function and tissue residency (Hoyler et al.,
2012; Mjo¨sberg et al., 2012; Wohlfert et al., 2011; Zheng and Fla-
vell, 1997). We found that lung GATA3+ Treg cells were also
strongly and preferentially induced by papain and IL-33,
compared to GATA3 Treg cells (17.7-fold compared to 7.1-
fold increase, respectively) (Figures S1A–S1D). GATA3+ Treg
cells in control (PBS), papain-, or IL-33-exposed lungs were
likely thymus derived, as indicated by co-expression of the tran-
scription factor Helios and the vascular endothelial growth factor
(VEGF) co-receptor neuropillin (Nrp)-1 (Figures 1A, 1B, and S1E;
Thornton et al., 2010; Yadav et al., 2012). GATA3+ Treg cells also
expressed more CTLA4 compared to GATA3 Treg cells in naive
and IL-33-treated mice (Figures 1C and S1F). We purified Th2
cells, GATA3+ and GATA3 Treg cells, and ILC2s from naive
and IL-33-treated Foxp3EGFP-DTR/+Gata3hCD2/+ mice and per-
formed RNA-seq gene expression analysis (Figures 1D, S1G,
and S1H, and Tables S1 and S2). Gene expression data were
consistent with flow cytometry findings. Moreover, we observed
substantial overlap between ILC2s, GATA3+ Treg cells, and Th2
cells during homeostasis and after in vivo IL-33 stimulation, sup-
porting the idea of shared regulatory and functional programs
between these cells (Panduro et al., 2016; Siede et al., 2016).
IL-33 is known to have direct effects on Treg cells, which ex-
press its receptor ST2 (Figure S1I; Schiering et al., 2014). How-
ever, we observed no significant proliferative advantage of
ST2+ over ST2 Treg cells after IL-33-induced expansion as as-
sessed by Ki67 staining, or in an adoptive transfer experiment of
mixed WT and Il1rl1/ CD4+ T cells, thus suggesting that an
alternative mechanism contributes to IL-33-mediated Treg cell
expansion (Figures S1J–S1M). Given that ILC2s can regulate
Th2 cells in vivo via direct (Drake et al., 2014; Mirchandani
et al., 2014; Oliphant et al., 2014) and indirect (Halim et al.,
2014, 2016) mechanisms and can regulate Treg cells via an
ICOS-ICOSL interaction in vitro (Molofsky et al., 2015), we tested
whether IL-33-driven Treg cell expansion was ILC2 dependent in
twomodels of ILC2 deficiency (Figures S2A and S2F). The 2W1S
peptide immunogen, co-administered with IL-33, was used
to track antigen-specific CD4+ T cell responses using the
2W1S:I-Ab MHCII tetramer (Moon et al., 2007). We found that
both antigen-specific and non-specific (2W1S:tetramer+ and )
Treg and Th2 cell responses were impaired in ILC2-deficient
Il7raCre/+Rorafl/fl mice (Figures 1E, S2B, and S2C). As a subset
of CD4+ T cells can also express Rora, we generatedp3+GATA3+ and  Treg cells and Foxp3GATA3+ Th2 cells in the lung on day 5.
33 and 2W1S-peptide as indicated (i.n., day 0 and 1), followed by quantification
mLN on day 5.
cent gated population in (A); (D), single experiment; (E), ANOVA, three repeat
experiments. ns = not significant, *p % 0.05, **p % 0.01, ***p % 0.001,
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Cd4Cre/+Rorafl/fl mice, which showed no defect in type 2 im-
mune-mediated expulsion of N. brasiliensis, or in Th2 or Treg
cell numbers after allergen or IL-33 challenge, supporting our
previous in vitro results (Figures 1F, S2D, and S2E; Halim et al.,
2012b; Wong et al., 2012). Additionally, using a separate model
of ILC2 deletion in diphtheria toxin (DTx)-treated ICOS-T
mice (Oliphant et al., 2014), we observed a similar defect in
GATA3+ Treg and Th2 cell responses after IL-33 + 2W1S peptide
administration (Figures 1G and S2F–S2H). As reported previ-
ously, ILC3s may also be impaired by DTx in Icosfl-DTR-fl/+
Cd4Cre/+ (ICOS-T) mice, although lung ILC3s are sparse and
not substantially affected by IL-33-driven inflammation (Figures
S2G and S2H). Further, to investigate a potential role for B cells,
we injected B cell-deficient Ighm/ (mMT) mice with IL-33, fol-
lowed by analysis for Th2 and Treg cells. We observed no signif-
icant difference in IL-33-driven Treg and Th2 cell expansion in
the lungs of mMT compared to WT mice (Figures S2I and S2J).
Moreover, immunofluorescence microscopy analysis of IL-33-
treated WT mice showed co-localization of Treg cells and
ILC2s in the lungs (Figure S2K), as reported previously (Molofsky
et al., 2015). Thus, ILC2s are critical for allergen- and IL-33-
induced expansion of Th2 cells and GATA3 and GATA3+
Treg cells.
OX40 Is Required for Expansion of Adaptive Type 2
Immunity by IL-33
We investigated possible cell-to-cell interactions that may influ-
ence IL-33-driven Th2 and Treg cell expansion and first
focused on T cell co-receptors. Gene expression analysis for
the tumor necrosis factor (TNF) receptor-superfamily was con-
ducted using lung ILC2s and other IMMGEN (Heng et al., 2008)
immune cell datasets (Figure 2A). We observed high expression
of Tnfrsf4 (OX40), an important T cell co-stimulatory receptor
(Croft, 2010), on Treg and activated CD4+ T cells. We
confirmed that OX40 was expressed on lung GATA3+ and
GATA3 Treg cells in PBS, papain-, or IL-33-stimulated mice,
but not Foxp3GATA3CD4+ T cells (Figures 2B, 2C, and
S3A). OX40 was also expressed on a smaller proportion of
Th2 cells after IL-33 administration (Figure 2B). We hypothe-
sized that OX40 may be important for mediating the IL-33-
driven expansion of Th2 and Treg cells. Using Tnfrsf4/
mice, we determined that the OX40 co-stimulatory molecule
was essential for IL-33-mediated Treg cell expansion in the
lungs (Figures 2D–2F). We observed similar requirements of
OX40 for the development of lung Th2 cells in response to IL-
33, while ILC2 expansion was unaffected (Figure S3B).
Tnfrsf4/ mice also showed a similar defect in adaptive type
2 immunity after intranasal administration of papain (Figures
2G–2I). Thus, OX40 signaling is critical for the induction of IL-
33-dependent adaptive type 2 immunity.
ILC2s Selectively Express OX40L in Response to IL-33
Next, we identified the critical OX40L-expressing cells by
analyzing gene expression for Tnfsf4 and other TNF superfamily
ligand transcripts. We found that Tnfsf4 (OX40L) gene expres-
sion was highest in naive lung ILC2s and substantially lower
in any of the other tested immune cells (Figure 3A). To confirm
these findings, we assessed OX40L expression on lung im-
mune cells in mice stimulated intranasally with IL-25, IL-33,1198 Immunity 48, 1195–1207, June 19, 2018TSLP, papain, LPS, or PBS. While control mice did not show
OX40L protein expression on any cells that we analyzed
(ILC2s, B cells, CD4+ and CD8+ T cells, DCs, Macs, and NK
cells), only ILC2s showed a significant induction of OX40L sur-
face expression upon IL-33, papain, and to a lesser degree IL-
25, stimulation (Figures 3B, 3C, and S4A–S4C). Moreover, lung
DCs from adult mice failed to induce OX40L expression in
response to intranasal administration of any of these stimuli,
including two separate TSLP formulations and anti-CD40
mAb treatment (Figure S4D). Also, OX40L+ ILC2s significantly
outnumbered OX40L+ DCs after IL-33 administration and also
exhibited higher intensity surface staining of OX40L (Fig-
ure S4E). Notably, human ILC2s also strongly induced OX40L
after IL-33 stimulation (Figure S4F). Additionally, IL-33 adminis-
tration to mice by intranasal (i.n.) or intraperitoneal (i.p.) routes
rapidly (day 2) increased Treg cell proliferation in the lung but
not mediastinal lymph node (mLN), while ILC2s at both sites
were activated and expressed ST2 (Figures 3D and S4G).
When we measured the expression of OX40L on ILC2s after
IL-33 administration, we observed that lung ILC2s expressed
OX40L, while mLN ILC2s and ILC3s did not (Figure 3E). Lastly,
proliferation of total CD4+ T cells was not significantly affected
in either lung or mLN by IL-33 administration (Figure S4H). This
led us to speculate that IL-33-driven local expansion of
adaptive type 2 immune cells is governed by ILC2-restricted
OX40L expression.
OX40L Expression by ILC2s Correlates with Tissue-
Specific T Cell Proliferation
To further ascertain the importance of OX40L expression
by ILC2s following IL-33-driven induction of adaptive type 2
immunity, we crossed Tnfsf4fl/fl mice with Il7rCre/+ mice.
Although other immune cells such as ILC3s and CD4+ T cells
also express IL7Ra, we did not observe OX40L expression in
these populations. Efficient deletion of OX40L on ILC2s was
achieved in Il7rCre/+Tnfsf4fl/fl mice, as indicated by reduced
expression of OX40L on lung ILC2s after IL-33 administration
(Figures 4A and S5A). Next, we asked whether ILC2-targeted
deletion of OX40L influenced the IL-33-driven effects on adap-
tive type 2 immunity. We administered IL-33 to Il7rCre/+,
Il7rCre/+Rorafl/fl, and Il7rCre/+Tnfsf4fl/fl mice on days 0 and 1, fol-
lowed by analysis on day 5. Notably, Il7rCre/+Tnfsf4fl/fl mice
failed to induce Th2 cells and GATA3+ and GATA3 Treg cell
responses in the lungs after treatment (Figures 4B–4D). The
observed defect produced a phenotype similar to naive control
or IL-33-treated Il7rCre/+Rorafl/fl mice. We subsequently investi-
gated lung, large intestine, and perigonadal adipose tissue for
the IL-33/ILC2/OX40L-driven effect on adaptive type 2 immu-
nity. Here we noted clearly divergent phenotypes with OX40L
expression induced only on lung and adipose tissue-resident
ILC2s but not in the intestine (Figure 4E). Nevertheless, ILC2
and ILC3 numbers in Il7rCre/+Tnfsf4fl/fl mice were similar to
those in control mice (Figures 4F, S5B, and S5D). Moreover,
only these two sites exhibited IL-33-driven expansion of Th2
cells and GATA3+ and GATA3 Treg cells (Figures 4G and
S5C). Importantly, ILC2-targeted deletion of OX40L phenocop-
ied ILC2 deficiency. This indicated the critical nature of OX40L
expression by ILC2s for establishing tissue-specific adaptive
type 2 immunity.
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Figure 2. OX40 Is Critical for Th2 and Treg Cell Response to IL-33 and Papain
(A) TNFRSF gene expression was analyzed in the indicated immune cell populations using IMMGEN and naive lung ILC2 microarray data.
(B and C) OX40 expression was analyzed on lung GATA3+ and GATA3 Treg and Th2 cells on day 5 from WT mice treated with PBS, papain, or IL-33 (i.n., day 0
and 1). Fluorescence minus one (FMO) control was used to establish gating threshold. Percent OX40+ cells were calculated in the indicated populations and
treatments and compared to Foxp3GATA3 (DN) CD4+ T cells.
(D–F) Lung GATA3+ and GATA3 Treg and Th2 cells were quantified from WT and Tnfrsf4/ mice on day 5 after IL-33 treatment (i.n., day 0 and 1).
(G–I) Lung GATA3+ and GATA3 Treg and Th2 cells were quantified from WT and Tnfrsf4/ mice on day 5 after papain (Pap) treatment (i.n., day 0 and 1).
Bar graphs indicate mean (±SEM). (A), two independent datasets per group; (B) and (C), ANOVA, two repeat experiments; (D)–(F), ANOVA, two repeat experi-
ments; (G)–(I), ANOVA, two repeat experiments. ***p% 0.001, ****p% 0.0001. See also Figure S3.OX40L on ILC2s Is Specifically Required for IL-33-
Driven Effects on Adaptive Type 2 Immunity
OX40L is reported on other IL7Ra+ cell types, including CD4+
T cells and RORgt+ ILC3s, and is widely described on CD11c+
DCs (Kim et al., 2005; Webb et al., 2016). While we observed
only OX40L on ILC2s after IL-33 stimulation, IL7RaCre-driven
deletion of OX40L is not entirely ILC2 specific. To better control
for possible OX40L signaling contributions from other immune
cells, we intercrossed Tnfsf4fl/fl mice with ItgaxCre, RorcCre/+,
and Cd4Cre/+ mice to further exclude non-ILC2-driven effects.
As before, we administered IL-33 to the indicated control orOX40L-targeted mice, followed by analysis for induction of
adaptive type 2 immunity. While ILC2-deficient and ILC2-tar-
geted OX40L-deficient Il7rCre/+Tnfsf4fl/fl mice both failed
to induce GATA3+ Treg, GATA3 Treg, and Th2 cells, mice
with DC-targeted (ItgaxCreTnfsf4fl/fl), ILC3-targeted (RorcCre/+
Tnfsf4fl/fl), and CD4+ T cell-targeted (Cd4Cre/+Tnfsf4fl/fl) OX40L
deletion showed no deficit compared toOX40L-sufficient control
mice (Figures 5A–5C). Finally, we generated Il7rCre/+Rorafl/fl +
Il7rCre/+Tnfsf4fl/fl mixed bone marrow (BM) chimeric mice, in
which ILC2s are OX40L deficient, to further investigate the role
of OX40L on ILC2s (Figure S6D). The mixed BM chimerasImmunity 48, 1195–1207, June 19, 2018 1199
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Figure 3. ILC2s Are the Main OX40L-Expressing Cell in Response to IL-33
(A) TNFSF gene expression was analyzed in the indicated immune cell populations using IMMGEN and naive lung ILC2 microarray data.
(B) OX40L expression was measured on lung DCs or ILC2s in WT mice on day 2 after treatment with PBS or IL-33 (i.n., day 0 and 1).
(C) The percentage of OX40L+ ILC2s (top) and DCs (bottom) was measured on day 2 in response to the indicated stimuli (i.n., day 0 and 1).
(D) The percent of Ki67+ ILC2s and Treg cells was measured on day 2 after treatment with PBS or IL-33 (day 0 and 1).
(E) OX40L expression was measured on ILC2s and ILC3s in the lung or mLN on day 2 after PBS or IL-33 treatment (i.n., day 0 and 1).
Numbers in (B) and (E) indicate percent (mean ± SD) gated populations. (A), two independent datasets per group; (B), three repeat experiments; (C), ANOVA, two
repeat experiments; (D), ANOVA, two repeat experiments; (E), two-tailed Student’s t test, two repeat experiments. ***p % 0.001, ****p % 0.0001. See also
Figure S4.showed a significant reduction, similar to ILC2-deficient BM
chimeric mice, in GATA3+ and GATA3 Treg cells after IL-33
administration compared to control mice (Figures 5D and 5E).
Thus, OX40L expression on ILC2s is essential for IL-33-driven
activation of adaptive type 2 immunity.
IL-33-ILC2-OX40L Pathway Is Critical for Allergen-
Induced Adaptive Type 2 Immunity
Protease allergens are potent inducers of IL-33 in the airways,
which is a central mechanism by which they drive innate and
adaptive type 2 immunity (Halim et al., 2012a; Hammad and
Lambrecht, 2015). In addition to Th2 cells, we investigated the
role of IL-33 in mediating allergen-induced Treg cell responses
in the lungs. Administration of the protease allergen papain led
to an induction of lung GATA3+ and GATA3 Treg cells on day
5 in WT mice (Figures 6A, 6B, and S7A). Papain-induced Treg
cell responses were significantly reduced in Il33cit/cit (Il33/) or
Il1rl1/ mice (Figures 6A and 6B), indicating the importance of
IL-33 for mediating allergen-induced expansion of Treg cells in
the airways. As expected, Th2 cells were also significantly
reduced in Il33cit/cit or Il1rl1/ mice compared to WT controls
(Figures 6C and 6D). We then investigated the role of ILC2-ex-
pressed OX40L for driving adaptive type 2 immunity in the lungs1200 Immunity 48, 1195–1207, June 19, 2018after papain exposure. We observed a failure of Th2 cells and
GATA3+ and GATA3 Treg cells to develop in the lungs of
Il7rCre/+Tnfsf4fl/fl mice (Figures 6A–6D). Next we exposed
Il7rCre/+, Il7rCre/+Rorafl/fl, and Il7rCre/+Tnfsf4fl/fl mice to repeat
exposures of papain after initial sensitization, followed by anal-
ysis of the lungs for multiple parameters of innate and adaptive
type 2 inflammation (Figure S7B). On day 24 we found that
Il7rCre/+Tnfsf4fl/fl mice had significant reductions in Th2 cells
and GATA3+ and GATA3 Treg cells compared to Il7rCre/+ con-
trols (Figures S7C–S7E). These reductions were similar to those
observed in ILC2-deficient mice. We also observed significant
reductions in lung eosinophilia (Figure 6E) and M2 polarization
by lung macrophages as assessed by intracellular staining for
RELMa (Figures 6F and 6G; Nair et al., 2009). We further investi-
gated whether OX40L expression by ILC2s may influence adap-
tive type 2 immunity to another allergen. Administration of
Alternaria alternata extract promoted an increase in lung Th2
cells, but alsoGATA3+ and – Treg cells by day 9, that was impaired
in Il7rCre/+Tnfsf4fl/flmice (Figure 6H). Moreover, we found that the
A. alternata induced increase in serum IgE was reduced in
Il7rCre/+Tnfsf4fl/fl mice (Figure 6I). Interestingly, CD11cCre tar-
geted OX40L deletion also resulted in reduced Th2 and Treg
cells after A. alternate-induced airway inflammation (Figure S7F),
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Figure 4. OX40L Expression by ILC2s Is Essential for Tissue-Specific Adaptive Immune Response to IL-33
(A) OX40L expression on lung ILC2s in the specified genotypes on day 2 after IL-33 administration (i.n., day 0 and 1).
(B–D) Lung GATA3+ and GATA3 Treg and Th2 cell numbers were quantified on day 5 after treatment with PBS or IL-33 (i.n., days 0 and 1).
(E–G) OX40L expression on ILC2s wasmeasured in the indicated tissues (L. int., large intestine) after treatment with PBS or IL-33 (days 0 and 1) on day 2 (E), while
the number of ILC2s (F) and GATA3+ Treg cells was quantified on day 5 (G).
Numbers in (A) and (E) indicate percent (mean ± SD) gated populations. Bar graphs indicate mean (±SEM). (A), three repeat experiments; (B)–(D), ANOVA, two
repeat experiments; (E)–(G), ANOVA, two repeat experiments. *p% 0.05, **p% 0.01, ****p% 0.0001. See also Figure S5.suggesting that both DC- and ILC2-derived OX40L contribute to
the response. Thus, ILC2-expressed OX40L is critical for medi-
ating ILC2-induced innate and adaptive type 2 inflammation to
allergen exposure in an IL-33-dependent pathway.
OX40L-Expressing ILC2s Are Essential for Adaptive
Type 2 Immunity to Helminth Challenge
To interrogate the importance of the ILC2-OX40L axis in com-
plex immune challenges, we used the prototypical type 2 immu-
nity-inducing parasitic helminth, N. brasiliensis, which traffics
through the lung after infection, inducing profound and pro-
longed type 2 inflammation (Mohrs et al., 2001). Besides Th2
cells, Treg cells are known to play an important role for wound
healing and tissue remodeling of the lung (Chen et al., 2012; Tay-
lor et al., 2012). First, we characterized the adaptive type 2
immune response in the lungs of mice on day 28 after
N. brasiliensis infection and observed substantial increases in
GATA3+ and GATA3 Treg cells and Th2 cells in control mice
(Figures 7A–7C and S7G). By contrast, Il7rCre/+Tnfsf4fl/flmice ex-
hibited a failure of the lung Th2 cells and GATA3+ and GATA3
Treg cells to expand, with numbers remaining similar to unin-
fected control mice. Notably, this impairment mirrored that
measured in Il7rCre/+Rorafl/fl mice (Figures 7A–7C). Lung histol-
ogy demonstrated that Il7rCre/+Tnfsf4fl/flmice had reduced histo-
logical features of inflammation compared to infected controlmice (Figure 7D), again similar to those in Il7rCre/+Rorafl/fl mice.
While infected control mice mounted a prolific eosinophil
response, we observed an impairment in Il7rCre/+Tnfsf4fl/fl mice
to induce eosinophilia in the lung (Figure 7E) or BAL (Figure 7F).
Similar impairments were observed when we quantified RELMa+
M2 polarized lungmacrophages (Figure 7G) and BAL concentra-
tions of IL-4 and IL-5 (Figure 7H), while IL-13+ Th2 cells were
also significantly reduced in the lungs of Il7rCre/+Tnfsf4fl/fl
compared to control mice (Figure 7I). Moreover, by day 28 after
infection, we observed a reduction of adaptive type 2 CD4+
T cells in the mLN, and total lung IgE concentration of both
infected Il7rCre/+Rorafl/fl and Il7rCre/+Tnfsf4fl/fl mice compared
to controls (Figures 7J–7M). Furthermore, at 5 days after
N. brasiliensis infection, we observed a modest increase in
worm numbers of Il7rCre/+Tnfsf4fl/fl mice compared to control
mice (Figure 7N). Of note, while absolute cell numbers were
reduced, we observed no reduction in Th2 cell frequency in in-
fected Il7rCre/+Rorafl/fl or Il7rCre/+Tnfsf4fl/flmice compared to con-
trol mice. Moreover, no significant differences were observed in
type 1 immunity (IFN-g production), NK cells, and CD8+ T cells of
both Il7rCre/+Rorafl/fl and Il7rCre/+Tnfsf4fl/flmice compared to con-
trols after infection (Figures S7H–S7K). Thus, these results indi-
cate that the IL-33/ILC2/OX40L axis is broadly important for
orchestrating innate and adaptive type 2 immunity following hel-
minth challenge.Immunity 48, 1195–1207, June 19, 2018 1201
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Figure 5. OX40L-Driven Response to IL-33 Is Restricted to ILC2s
(A–C) Lung GATA3+ and GATA3 Treg cells and Th2 cells were quantified on day 5 in the specified genotypes, treated with PBS or IL-33 (i.n., days 0 and 1).
(D and E) Bone marrow and mixed-bone marrow chimeric mice were created with the indicated genotypes. 6 to 7 months after bone marrow transfer, mice
received IL-33 (i.n., days 0 and 1) followed by quantification of lung GATA3+ Treg (D) and GATA3 Treg (E) cells on day 5.
Bar graphs indicate mean (±SEM). ANOVA, two repeat experiments. ns = not significant, *p% 0.05, **p% 0.01, ***p% 0.001, ***p% 0.0001. See also Figure S6.DISCUSSION
The potential role of ILC2s as key potentiators of immune activa-
tion, performing as intermediaries between the damaged epithe-
lium and the adaptive immune system, is currently an important
and unresolved question. While previous studies have started to
reveal mechanisms by which ILC2s can influence Th2 cell prim-
ing (Halim et al., 2014, 2016; Mirchandani et al., 2014; Oliphant
et al., 2014), the continued importance of ILC2s in the presence
of adaptive type 2 immunity is unclear (Van Dyken et al., 2016;
Ve´ly et al., 2016), especially because Th2 and Treg cells may
also be directly activated by IL-33 (Guo et al., 2015; Schiering
et al., 2014).
Our results using ILC2-deficient mouse models indicated that
IL-33-driven expansion of Th2 and Treg cells was dependent on
ILC2s. As RORa is also expressed by T cells, it has been sug-
gested that deletion of Rora in lymphocytes may directly alter
T cell responses. Significantly, using Cd4Cre/+Rorafl/fl mice, we
excluded the possibility that Rora deletion results in CD4+
T cell-intrinsic effects that diminish adaptive immunity. Indeed,
we demonstrated that mice whose T cells lack RORa mounted
equivalent type 2 adaptive immune responses to parasitic
worm infection, papain allergen, and IL-33 as RORa-sufficient
T cell controls.
To further elucidate the mechanism by which ILC2s can
orchestrate Th2 and Treg cell responses, we identified costimu-
latory molecules that were counter-expressed on ILC2s and
T cells. Gene expression data highlighted the potential impor-
tance of OX40/OX40L interactions, which have been linked pre-1202 Immunity 48, 1195–1207, June 19, 2018viously with the development of Th2 cell responses (Croft, 2010;
Webb et al., 2016). OX40 is expressed on memory T cells after
TCR-mediated recall responses (Croft, 2010) and is also associ-
ated with Treg cell homeostasis and function (Takeda et al.,
2004). Additionally, we discovered that OX40L, which has been
reported on other immune cells in response to type 2 alarmins
(Croft, 2010; Webb et al., 2016), was increased on lung ILC2s
in response to IL-33.
Notably, we were unable to detect OX40L on lung-resident
dendritic cells, or other lung cell populations, even after treating
mice with TSLP. Although OX40L mRNA expression is reported
in many models of type 2 inflammation, and OX40L protein
expression can be induced on in vitro cell-cultured mouse and
human DCs stimulated with various cytokines (e.g., TSLP) and
antigens, the cellular expression of OX40L protein in vivo remains
relatively opaque. Nevertheless, while alarmin stimulation did not
induce OX40L expression on lung-resident DCs, our study with
A. alternata-induced lung inflammation clearly showed a role
for OX40L expression by CD11c+ cells, confirming previous find-
ings of impaired Th2 cell priming of OX40L-deficient DCs (Jen-
kins et al., 2007). As we did not observe OX40L on ILC2s in the
draining mLNs, it appears that separate functions of OX40L are
enforced by distinct cell types.
Moreover, while IL-33-mediated expansion of Th2 and Treg
cells may involve an antigen-independent mechanism solely
reliant on ILC2s, more complex antigens such as A. alternata
and house dust mite activate multiple cellular targets, including
DCs (de Kleer et al., 2016). Similarly, neonatal mouse DCs in
the lung transiently express OX40L, suggesting differential
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Figure 6. OX40L on ILC2s Orchestrates Adaptive Type 2 Immunity to Allergens
(A–D) Mice of the specified genotypes were treated with PBS or papain (Pap) (i.n., day 0 and 1), followed by quantification of lung Th2, GATA3+ Treg, and GATA3
Treg cells on day 5 (A–C). Whole lung cell suspensions were re-stimulated with PMA and ionomycin, followed by quantification of IL-13+ Th2 cells by intracellular
staining (D).
(E–G) Mice were treated with papain on days 0, 1, 14, and 21, followed by quantification on day 24 of lung eosinophils (E), and detection (F) and quantification (G)
of RELMa+ M2 alveolar (CD45+SiglecF+CD11c+CD11bF4/80+) macrophages (MF).
(H and I) Mice were treatedwithA. alternata (A.alt) (i.n., days 0 and 1), followed by quantification on day 9 of lung Th2, GATA3+ Treg, andGATA3 Treg cells (H) and
serum IgE concentration (I).
Bar graphs indicate mean (±SEM). (A)–(D), ANOVA, two repeat experiments; (E), ANOVA, three repeat experiments; (F) and (G), ANOVA, two repeat experiments,
representative gate shown in (F); (H) and (I), ANOVA, two repeat experiments. **p% 0.01, ***p% 0.001, ****p% 0.0001. See also Figure S7.expression patterns dependent on developmental stage (de
Kleer et al., 2016). Thus, ILC2- and DC-expressed OX40L may
play partially compensatory roles and further study is required
to resolve the complexity of how differing temporal expression,
tissue environment, and the nature of the antigen encountered
may influence the induction of these pathways in protecting
the host.
We observed that OX40-deficient mice and mice with a
conditional deletion of OX40L (Il7rCre/+Tnfsf4fl/fl) had significantly
impaired Th2 and Treg cell responses following IL-33 administra-
tion, a phenotype similar to ILC2-deficient mice. Furthermore,
mixed BM chimeric mice, in which only ILC2s were OX40L
deficient, also failed to induce Treg cells following IL-33 admin-
istration. By contrast, conditional deletion of OX40L from
T cells, dendritic cells, and ILC3s resulted in normal IL-33-
induced responses. The deletion of OX40L from ILC2s also
curtailed the onset of type 2 immunity in the lungs of mice admin-
istered papain allergen or infected with parasitic helminths.
Thus, OX40L expression on ILC2s, but not DCs, is essential
for the robust onset of IL-33-induced type 2-mediated lung
inflammation.
Previous studies have demonstrated that OX40- and OX40L-
deficient mice fail to develop type 2 responses characteristicof allergic lung inflammation (Hoshino et al., 2003; Jember
et al., 2001) and showed that OX40L-deficient (Tnfsf4/) mice
were less efficient at responding to Heligmosomoides polygyrus
(Ekkens et al., 2003). We now establish ILC2s, through their tis-
sue-specific expression of OX40L in response to IL-33, as critical
players in the local expansion of OX40-expressing Th2 and Treg
cells and the initiation and maintenance of robust type 2 re-
sponses in the lung. The co-induction of Th2 and Treg cells via
the same signaling pathways may serve to limit allergic inflam-
mation, as indicated by the suppressive role of Treg cells on
Th2 cell-driven lung inflammation (Suto et al., 2001), while also
promoting wound healing such as in response to helminth-
induced damage (Pulendran and Artis, 2012). Indeed, we
showed that N. brasiliensis-induced adaptive type 2 immunity,
important for lung damage repair (Chen et al., 2012), is depen-
dent on OX40L expression on ILC2s. Accordingly, we observed
a profound reduction in eosinophils, alternatively activated
Macs, and type 2 effector cytokines. Importantly, ILC2s and
Treg and Th2 cells were detectable in normal numbers at base-
line in Il7rCre/+Tnfsf4fl/flmice, and type 1 immunity was unaffected
after immune challenge.
OX40L can be regulated in an age- and tissue-specific manner
and can be induced on a range of immune cells under variousImmunity 48, 1195–1207, June 19, 2018 1203
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Figure 7. ILC2-Expressed OX40L Is Essential for Airway Adaptive Type 2 Immune Response to Helminth Infection
Mice of the specified genotypes were infected with Nippostrongylus brasiliensis (N.b.) on day 0, followed by analysis on day 28 (or day 5) of:
(A–C) Lung Th2, GATA3+ Treg, and GATA3 Treg cell numbers.
(D) Representative lung histology (Mason’s trichrome).
(E and F) Lung (E) and bronchoalveolar lavage (F) eosinophil numbers.
(G) Lung RELMa+ M2 macrophage (MF) numbers.
(H) Bronchoalveolar lavage IL-4 and IL-5 cytokine concentrations.
(I) Whole lung cell suspensions were re-stimulated with PMA and ionomycin, followed by quantification of lung IL-13+ Th2 cell numbers by intracellular staining.
(J–L) Mediastinal lymph node Th2, GATA3+ Treg, and GATA3 Treg cell numbers.
(M) Concentration of IgE present in lung homogenate, normalized for total protein content.
(N) Intestinal worm burden of indicated mouse genotypes 5 days post infection.
Bar graphs indicate mean (±SEM). (A)–(C), ANOVA, three repeat experiments; (D), two repeat experiments; (E)–(I), ANOVA, two repeat experiments; (J)–(L),
ANOVA, three repeat experiments; (M), ANOVA, two repeat experiments; (N), two-tailed Student’s t test, two pooled experiments. ns = not significant, *p% 0.05,
**p% 0.01, ***p% 0.001, ****p% 0.0001. See also Figure S7.inflammatory conditions (Croft, 2010; de Kleer et al., 2016;Webb
et al., 2016). The availability of a conditional OX40L allele will be
of significant importance in continuing to identify critical cellular
sources of OX40L in mouse models. For example, whether
OX40L on ILC2s, in addition to DCs, is also instructive during
neonatal establishment of persistent Th2 and Treg cells in
response to IL-33 is unknown but of critical importance (de Kleer
et al., 2016; Gollwitzer et al., 2014; Saluzzo et al., 2017; Steer
et al., 2017). In adult mice, however, we implicated OX40L1204 Immunity 48, 1195–1207, June 19, 2018expression on ILC2s in diverse lung pathologies. Other cellular
signaling molecules such as ICOSL and PD-1L may also influ-
ence cross-talk between ILC2s and T cells, although the magni-
tude of the ILC2-specific effect and broad expression of these
ligands on other immune cells suggests a different role
compared to OX40L (Molofsky et al., 2015; Schwartz et al.,
2017). The tissue-specific OX40L expression profile of ILC2s
was an intriguing finding that warrants further investigation. Envi-
ronmental cues or developmental programs may influence the
response and/or sensitivity of ILC2s to IL-33. Intestinal ILC2s ex-
press ST2 but are known to be more sensitive to IL-25 than lung
ILC2s. Nevertheless, mLN ILC2s were activated by IL-33 but do
not express OX40L. Whether ILC2s are directly involved in
regulating follicular T and B cell responses is an intriguing ques-
tion, given our observation of reduced IgE concentrations in
Il7rCre/+Tnfsf4fl/fl mice after allergen or helminth exposure, and
the known function of OX40 in humoral immunity (Cortini et al.,
2017; Gaspal et al., 2005; Jember et al., 2001; Tahiliani et al.,
2017). Significantly, delineating the effect of OX40L expression
by ILC2s and other immune cells in specific anatomical locations
will aid the refinement of proposed immunotherapies targeting
the OX40L/OX40 interaction (Gauvreau et al., 2014; Linch
et al., 2015).
While important for establishing adaptive type 2 inflammation
in the airways, we have not resolved the functional significance
of the parallel ILC2-driven expansion of Treg cells. While Treg
cells can suppress type 2 inflammation (Lewkowich et al.,
2005; Morita et al., 2015; Suto et al., 2001), a more synergistic
role is observed in cases of type 1 immune suppression, wound
healing, and metabolism. This synergy, in addition to similarities
in development, led to the hypothesis that Treg cell function can
intersect with that of Th2 cells (Chapoval et al., 2010; Panduro
et al., 2016). We indeed observed a substantial overlap in gene
expression profiles between Th2 cells and Treg cells, but also
ILC2s. Many of these genes such as Irf4, Gata3, Nrp1, Areg,
and Il1rl1 have shared functions between these lineages (Arpaia
et al., 2015; Monticelli et al., 2011; Odegaard and Chawla, 2015;
Siede et al., 2016; Vasanthakumar et al., 2015). Moreover, lung
GATA3+ Treg cells were strongly induced by protease allergens
and IL-33, and our data support previous findings that assign
enhanced effector function to this subset (Wohlfert et al.,
2011). Further studies are required to dissect the IL-33-ILC2-
OX40L axis on specific Treg cell subsets in homeostasis and
disease.
In conclusion, we have revealed a critical immune-regulator
checkpoint for tissue-specific orchestration of adaptive type 2
immunity, whereby the potent effect of the alarmin IL-33 on
adaptive immunity is contingent on its upregulation of OX40L
by ILC2s.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
In vivo animal studies
C57BL/6 (B6), B6.Il33cit/cit (Il33/), B6.Il1rl1/, B6.Tnfrsf4/, B6.Il7rCre/+ (Schlenner et al., 2010), B6.Il7rCre/+Rorafl/fl,
B6.RorcCre/+Tnfsf4fl/fl, B6.Tnfsf4fl/fl mice (Cortini et al., 2017), B6.Il7rCre/+Tnfsf4fl/fl, B6.Foxp3DTR-egfp/+, B6.Cd4CreTnfsf4fl/fl,e3 Immunity 48, 1195–1207.e1–e6, June 19, 2018
B6.Cd4CreRorafl/fl, B6.Foxp3DTR-egfp/+Gata3hCD2/+ (B6.Gata3hCD2/+ mice, manuscript in preparation, J.A.W. and A.N.J.M),
B6.Cg-Tg(Itgax-EGFP-CRE-DTR-LUC)2Gjh/Crl, B6.ItgaxCre/+Tnfsf4fl/fl, B6.iCOS-T (B6.Icosfl-DTR-fl/+Cd4Cre/+) (Oliphant et al., 2014), B6.
Ighmtm1Cgn/J, B6.Rag2/ andB6.RorcCre/+miceweremaintained in theMedical Research Council (MRC) ARES animal facility, under
specific-pathogen-free conditions. Animals were sex and age matched whenever possible, and most animals were used at
6-10 weeks of age (we used OX40/ mice that were over 12 weeks old, which have normal Treg cell number during homeostasis
(Takeda et al., 2004). All animal use was in accordance with the guidelines of the UK Home Office.
Human studies
Peripheral blood samples were obtained from healthy anonymous adult donors after written informed consent was given. Whole
blood was subjected to density centrifugation on Lymphoprep (STEMCELL Technologies) and peripheral bloodmononucleated cells
(PBMC) were collected from the interphase. All human work was approved by the appropriate UK research ethics committees
(15/EE/0408).
Primary cell culture
Human and mouse primary cells were cultured at 37C in a humidified, 5% CO2 incubator.
METHOD DETAILS
Primary leukocyte preparation
Cell suspensions were prepared from lung by mechanical dissociation, followed by digest in 3 mL of RPMI-1640 containing collage-
nase I (500 U/ml) and DNase I (0.2 mg/ml) for 45minutes at 37C on a shaker (220 rpm), followed by filtration through a 70 mm strainer
and 25%Percoll gradient enrichment of leukocytes and red blood cell (RBC) lysis. LNwas strained through a 70 mmstrainer with PBS,
followed by RBC lysis. BAL cells and fluid were obtained in PBS as described (Halim et al., 2014). Cell suspensions were prepared
from perigonadal adipose tissue by mechanical dissociation, followed by digest in 1 mL of RPMI-1640 containing collagenase I
(500 U/ml) and DNase I (0.2 mg/ml) for 45 minutes at 37C on a shaker (1100 rpm), followed by filtration through a 70 mm strainer
and RBC lysis. Cell suspensions were prepared from large intestine by initial cleaning with PBS (10 mM HEPES) and mechanical
dissociation, incubation in EDTA/DTT to remove intraepithelial cells, followed by digest in 8 mL of RPMI-1640 (10 mM HEPES) con-
taining Liberase (0.0625 mg/ml, Roche) and DNase I (0.2 mg/ml) for 30 minutes at 37C on a shaker (200 rpm), followed by filtration
through a 70 mmstrainer and Percoll gradient enrichment of leukocytes and red blood cell (RBC) lysis. Single-cells were re-stimulated
and stained for surface and intracellular markers as described below.
Flow cytometry
Single cells were incubated with anti-mouse CD16/32 (Thermo Fisher) to block Fc receptors and stained as indicated. Lineage cock-
tail contained (±CD3, ± NK1.1, TCRb, CD5, CD19, CD11b, CD11c, FcεR1a, F4/80, Ly-6C/G, and Ter119). For intracellular staining we
used the Foxp3/Transcription Factor Kit (Thermo Fisher). For intracellular cytokine detection, single cells were stimulated with PMA
(60 ng/ml) and ionomycin (500 ng/ml) and 1X protein transport inhibitor (Thermo Fisher) in culture media (RPMI-1640, 10% FCS) at
37C for 3 hours before staining. Flow cytometry analysis was performed on a BD Fortessa instrument. Cells were quantified using
CountBright beads or manual cell counting by hemocytometer. Flow cytometry data was analyzed using FlowJo X (Tree Star).
In vivo stimulation
Mice were anesthetized by isofluorane inhalation, followed by the intranasal administration of rmIL-25 (0.2 mg), rmIL-33 (0.2 mg),
rmTSLP (0.2 mg), LPS, Alternaria alternata extract (10 mg, Greer Laboratories), or papain (10 mg) in 40 ml of PBS. Diphtheria toxin
(300–500 ng), anti-CD40 mAb or IgG control (100 mg), or rmIL-33 (0.5 mg) was administered by intraperitoneal injection in 200 ml
PBS. For Nippostrongylus brasiliensis infections 500 live L3 larvae were injected subcutaneously in 100 ml of water.
Adoptive CD4+ T cell transfer
CD4+ T cells were enriched from naive B6 and B6.Il1rl1/mice using amagnetic bead negative selection strategy (Miltenyi Biotech).
CD4+ T cell enriched cells were quantified and equal numbers of each genotype was adoptively transferred to CD45.1 congenic
B6.Rag2/ recipient mice on day 5. Adoptively transferred mice where subsequently used as indicated.
Bone marrow transplantation
Recipient mice were lethally irradiated (2 doses of 4.5 Gy) followed by intravenous transplantation of 107 whole bone marrow cells
from 4-6 week old mice. Mice were given Baytril in drinking water for 4 weeks, and used for analysis at 24-32 weeks post transplant.
IF microscopy
Lungs were infused with 50% O.C.T. (Tissue-Tek) in PBS immediately after mice were killed. Lungs were subsequently frozen in
100% O.C.T. compound, followed by sectioning. 6 mm-thick sections of frozen lung tissue were cut, fixed in cold acetone at 4 C
for 20 min and then stored at 20 C before staining. Antibodies raised against the following mouse antigens were used: CD3 (bio-
tinylated, clone eBio500A2, Thermo Fisher), FoxP3 (APC conjugated, clone FJK-16 s, Thermo Fisher), GATA-3 (unconjugated, cloneImmunity 48, 1195–1207.e1–e6, June 19, 2018 e4
TWAJ, Thermo Fisher), IL-7Ra (efluor660 conjugated, clone A7R34, Thermo Fisher). Detection of GATA-3 expression required ampli-
fication of the signal: the primary antibodies were detected with donkey anti-rat-IgG-FITC (Jackson ImmunoResearch), then rabbit
anti-FITC-AF488 (Life Technologies) and then with donkey anti-rabbit-IgG-AF488 (Life Technologies). Biotinylated anti-CD3 anti-
bodies were detected with SA-AF555 (Life Technologies). Sections were counterstained with DAPI (Invitrogen) and mounted using
ProLong Gold (Invitrogen). Slides were analyzed on a Zeiss 780 Zen microscope (Zeiss).
Histology
All mouse lung lobes were weighed and a single lobe was used for histology. Lung lobes were fixed in 10% formaldehyde in PBS for
24 hours at 4C, followed by transfer to 70% Ethanol in PBS for 24 hours at 4C. Finally, lung lobes were transferred to PBS and kept
at 4C until paraffin embedding. Sections were cut and stained with Mason’s trichrome reagent. The CRUK Cambridge Institute His-
tology Core performed tissue embedding, sectioning and staining.
Human ILC2 culture
PBMCwere blockedwith TruStain FcX and stainedwith biotinylated aCD3, aCD14 and aCD19 for the depletion of T cells, monocytes
and B cells by MACS using M-280 streptavidin Dynabeads (Thermo Fisher), according to the manufacturer’s instructions. Following
further antibody staining, ILC2 were sorted from depleted PBMC based on surface marker expression as lineage negative (strepta-
vidin-APC, CD8a, CD11b, CD11c, FcεRIa, CD123, CD20, CD56, CD71), DRAQ7-, CD45+, CD127+ andCRTH2+ on aBD Influx. Sorted
ILC2 were cultured in RPMI (GIBCO) supplemented with 10% FBS, 100 mM 2-mercaptoethanol, 100 mg/mL penicillin, 100 IU/mL
streptomycin, 20mMHEPES and 10 ng/mL recombinant human IL-2, IL-7 and IL-33 (as indicated). OX40L surface protein expression
was assessed by flow cytometry after 72 hours of culture. Briefly, following Fc-receptor blocking, ILC2 were stained with lineage
antibodies (CD3, CD11b, CD19), OX40L and efluor780 fixable viability dye followed by acquisition on a BD LSR Fortessa flow cytom-
eter. Data was analyzed with FlowJo 10.2.
Gene expression analysis
We obtained microarray datasets for the listed cell-types (T.8Nve.Sp1/2, T.4Nve.SP5/6, T.4Mem4h62l.Sp1.2, T.4FP3+25+.Sp2/3,
B.Fo.Sp, MC.PC4/5, MF.11c-11b+.Lu, Mo.6C-II-Lu.v2, DC.103-11b+24+.Lu, GN.Bl, Eo.BL.v2, NKT.4+.SP1/2, NK.Sp7/8,
ILC1.CD127+.SP1/2, BA.SP1/3, LPL.NCR+ILC3.1/2,) from data assembled by the ImmGen consortium (Heng et al., 2008), which
was compared to our own lung ILC2 microarray data (Halim et al., 2012a). Data analysis was performed with FlexArray 1.5 (Genome
Quebec).
IgE measurement
Lungs were frozen in liquid nitrogen, then homogenized in PBS protein inhibitor (cOmplete EDTA free protease inhibitor tablets,
Roche), centrifuged to remove cell debris and supernatants were harvested. Total lung protein was measured using a BCA assay
(Thermo Fisher) and Lung and serum IgE concentrations were measured by ELISA assay (Thermo Fisher).
RNA-seq
Foxp3egfp+GATA3hDC2+ mice were treated with nothing or rmIL-33 (0.2 mg) in PBS (i/n, day 0 and 1) followed by collection of lung tis-
sue on day 5. Single cells were incubated with anti-mouse CD16/32 to block Fc receptors and stained with DAPI, anti-CD45, CD3,
CD4, B220, Lineage (NK1.1, Gr-1, CD11b, CD11b, Ter119, CD19, CD5, F4/80, FcεR1a), and hCD2mAb, followed by sorting of: DAPI
(Live) CD45+ B220 into CD3+ CD4+ eGFP(Foxp3)+/ hCD2(Gata3)+/ T cells, and DAPI(Live) CD45+ B220 Lineage CD3 CD4
hCD2(Gata3)+ ILC2. CLP were sorted from the bone marrow as CD45+ Lineage Sca-1int CD127+ Flt3+ cells. Cells were flow sorted
into PBS 2% FCS and transferred to Trizol LS (Life Technologies). chloroform extractions were performed and 1.5X volume of 100%
ethanol was added to the aqueous phase. RNA was extracted using RNeasy kit (QIAGEN), gDNA was digested using Turbo DNase
(Ambion), concentrated using RNeasyMicro Kit (QIAGEN) and assessed using the Bioanalyser (Agilent). RNAwas processed for RNA
sequencing using Ovation RNA-seq System V2 (Nugen), fragmented using the Covaris M220 and barcoded using Ovation Ultralow
Library Systems (Nugen). Samples were sequenced using the Illumina Hiseq4000 (CRUK Cambridge Institute) and aligned using
Tophat2 with Partek Flow. RPKM and differential gene transcript expression were generated using Genomics Suite software,
version 6.16 Copyright ª; 2016 Partek Inc., St. Louis, MO, USA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics
Data were analyzed using GraphPad Prism 6 (GraphPad Software). A Kruskal-Wallis one-way ANOVA with Bonferroni post-analysis,
or two-tailed Student’s t test was used to determine the statistical significance between groups with p% 0.05 being considered sig-
nificant (*), p% 0.01 = **, p% 0.001 = ***, p% 0.0001 = ****.e5 Immunity 48, 1195–1207.e1–e6, June 19, 2018
Additional details for main figures
Figure 1: (A-C, 3 repeat experiments, mean % gated population in A), (D, single experiment), (E, n = 4,4,4,4 left to right, ANOVA, 3
repeat experiments), (F, n = 5,5,5 left to right, ANOVA, 2 repeat experiments), (G, n = 4,4,4,4 left to right, ANOVA, 3 repeat
experiments)
Figure 2: (A, 2 independent datasets per group), (B-C, n = 5,5,5,5 left to right inC, ANOVA, 2 repeat experiments), (D-F, n = 10,9,10
left to right in D, n = 10,10,10 in E and F, ANOVA, 2 pooled repeat experiments), (G-I, n = 5,5,5 left to right, ANOVA, 2 repeat
experiments)
Figure 3: (A, 2 independent datasets per group), (B, n = 3, mean percent gated shown ± S.D., 3 repeat experiments),
(C, n = 3,3,3,3,3,3 left to right, ANOVA, 2 repeat experiments), (D, n = 4,4,4 left to right, ANOVA, 2 repeat experiments), (E, n = 4,
percent gated shown ± SD two-tailed Student’s t test, 2 repeat experiments)
Figure 4: (A, n = 4,4,4 left to right, percent gated shown ± S.D., 3 repeat experiments), (B-D, n = 4,8,8,8 left to right for B and C
n = 4,4,4,4 left to right forD, ANOVA, 2 repeat experiments), (E-G, n = 5,5, percent gated shown ± SD for E, n = 8,8,8,8 for F andG (n =
8,8,8,7 for Adipose), ANOVA, 2 pooled repeat experiments)
Figure 5: (A, n = 10,10,10 left to right, ANOVA, 2 pooled repeat experiments), (B, n = 10,10,10 left to right, ANOVA, 2 pooled repeat
experiments), (C, n = 5,5,5 left to right, ANOVA, 2 repeat experiments), (D and E, n = 10,10,10 left to right, ANOVA, 2 pooled repeat
experiments)
Figure 6: (A-D, n = 5,5,5,3,5 left to right, ANOVA, 2 repeat experiments), (E, n = 11,9,10 left to right, ANOVA, 3 repeat experiments
(2 pooled experiments shown)), (F-G, n = 5,4,5 left to right, ANOVA, 2 repeat experiments, representative gate shown in F), (H-I,
n = 5,5,5 left to right, ANOVA, 2 repeat experiments)
Figure 7: (A-C, n = 10,10,10,10 left to right, ANOVA, 3 repeat experiments (2 pooled experiments shown)), (D, 2 repeat experi-
ments), (E-I, n = 5,5,5,5 left to right, ANOVA, 2 repeat experiments), (J-L, n = 10,10,10,10 left to right, ANOVA, 3 repeat experiments
(2 pooled experiments shown)), (M, n = 5,5,5,5 left to right, ANOVA, 2 repeat experiments), (N, n = 10,13 left to right, two-tailed Stu-
dent’s t test, 2 pooled experiments)
DATA AND SOFTWARE AVAILABILITY
Microarray datasets for ILC2 are available under accession number GSE36057; all other microarray datasets are available under
GSE15907 and GSE37448. RNA-seq datasets are available in GEO (GSE112937).Immunity 48, 1195–1207.e1–e6, June 19, 2018 e6
